Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol: Meta-analysis

Archives of Gynecology and Obstetrics

Volumn 265, Issue 4, 2001, Pages 175-182

  Ludwig, M ^a   Katalinic, A ^b   Diedrich, K ^c  

^a University Clinic   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Assisted reproduction; Cetrorelix; Ganirelix; GnRH antagonists; Ovarian stimulation

Indexed keywords

BUSERELIN; CETRORELIX; GANIRELIX; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DATA ANALYSIS; DRUG USE; EVALUATION; FEMALE; HUMAN; INCIDENCE; INFERTILITY THERAPY; INTERMETHOD COMPARISON; META ANALYSIS; OVARY HYPERSTIMULATION; PREGNANCY RATE; STATISTICAL ANALYSIS;

CHORIONIC GONADOTROPIN; ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; ODDS RATIO; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 0035204025     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-001-0267-2     Document Type: Article

References (31)

1. Addition of GnRH antagonist in cycles of poor responders undergoing IVF
2. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: Results of a prospective randomized trial
3. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation
4. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the LHRH-antagonist cetrorelix (cetrotide) and the LHRH-agonist Buserelin
5. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the LHRH-antagonist cetrorelix (cetrotide) and the LHRH-agonist buserelin
6. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: Definition of high risk groups
7. Risks of GnRH angonist administration in early pregnancy. In ovulation induction
8. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction
9. Optimal protocol for gonadotropin releasing hormone agonist use in ovarian stimulation
10. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation
11. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women
12. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial
13. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages
14. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation
15. Myocardial infarction associated with ovarian hyperstimulation syndrome
16. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix in controlled ovarian stimulation for assisted reproduction
17. LHRH antagonist protocols in IVF do not lead to worse results than the long LHRH agonist protocol
18. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment
19. Scheduled administration of a gonadotrophin-releasing hormone antagonist (cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study
20. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
21. A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (cetrorelix) or a depot formula of a LH-RH agonist (triptorelin)
22. The single or dual administration of the LHRH antagonist cetrorelix prevents premature LH surges in an IVF-ET program
23. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins
24. Seven-day administration of the gonadotropin-releasing hormone antagonist cetrorelix in normal cycling women
25. Reduced in vitro fertlization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase
26. Comparable clinical outcome using the GnRH antagonist ganirelix or a long, protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation
27. A doubleblind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (puregon)
28. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
29. GnRH antagonist versus GnRH agonist - Is women's age a factor in choosing the appropriate protocol for IVF?